Altimmune to Showcase Expertise at Upcoming Virtual Conference
Altimmune, Inc. (NASDAQ: ALT), a dynamic biopharmaceutical company specializing in clinical-stage innovations, is poised to make an impact at the H.C. Wainwright 8th Annual MASH Virtual Conference. This exciting event will take place soon, and key figures from the company will engage in insightful discussions about their pioneering work in therapeutic solutions.
Meet the Presenters
The session will feature Vipin Garg, Ph.D., the Chief Executive Officer of Altimmune, alongside Scott Harris, M.D., the Chief Medical Officer. Together, they will speak about the company’s forward-thinking initiatives and their contributions to the biopharmaceutical field.
Details of the Conference Session
Participants can look forward to a unique avenue for gaining insights into Altimmune’s research and development focus. The conversation is expected to include information about innovative peptide-based therapeutics that the company is working on.
Conference Attendance Information
The session will be webcasted live, providing accessible information to stakeholders and enthusiasts alike. Attendees can access the webcast by visiting the Events section on the Altimmune website at the scheduled time.
About Altimmune
Altimmune is dedicated to advancing the field of biopharmaceutical research. The company's innovative approach includes the development of pemvidutide, which acts as a GLP-1/glucagon dual receptor agonist aimed at treating obesity and metabolic dysfunction-associated steatohepatitis (MASH). This groundbreaking work positions Altimmune at the forefront of addressing significant health challenges.
Commitment to Innovation
With a strong focus on next-generation treatments, Altimmune not only prioritizes therapeutic efficacy but also safety and patient quality of life. The commitment to cutting-edge research reflects Altimmune’s mission to transform how metabolic disorders are treated.
Stay Connected with Altimmune
For further updates, individuals are encouraged to follow Altimmune on various platforms. Regular updates about their research achievements and company news are shared on their LinkedIn and Twitter accounts, ensuring stakeholders stay informed.
Contact Information
For inquiries, interested parties can reach out directly to the company for further information:
Vipin Garg
President and Chief Executive Officer
Phone: 240-654-1450
Email: ir@altimmune.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Email: Danielle.cantey@inizioevoke.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
Email: lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
Email: jweilman@burnsmc.com
Frequently Asked Questions
What is the purpose of Altimmune's participation in the conference?
Altimmune aims to showcase its innovative therapeutic solutions and engage with stakeholders about its research advancements during the conference.
Who are the key speakers from Altimmune at the conference?
Vipin Garg, Ph.D., the CEO, and Scott Harris, M.D., the CMO, will represent Altimmune at the event.
What topics will be discussed during the conference?
The discussion will likely focus on Altimmune's developments in innovative peptide-based therapeutics.
How can I access the conference session?
The session will be available via webcast, accessible through the Altimmune website's Events section at the scheduled time.
What new therapies is Altimmune working on?
Altimmune is developing pemvidutide, targeting obesity and metabolic disorders, which is a significant step forward in biopharmaceutical therapies.